echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Thorac Cancer: Retrospective analysis of the efficacy of docetaxel combined with ramucirumab in second-line treatment of advanced NSCLC patients with advanced chemotherapy combined with immunotherapy

    Thorac Cancer: Retrospective analysis of the efficacy of docetaxel combined with ramucirumab in second-line treatment of advanced NSCLC patients with advanced chemotherapy combined with immunotherapy

    • Last Update: 2021-12-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Chemotherapy combined with immunotherapy has become the standard treatment option for patients with untreated advanced non-small cell lung cancer ( NSCLC )
    .
    However, many patients with advanced NSCLC develop disease progression after treatment


    .


    Chemotherapy combined with immunotherapy has become the standard treatment option for patients with untreated advanced non-small cell lung cancer ( NSCLC )


    The study included 88 patients with advanced NSCLC who received chemotherapy combined with immunotherapy in 6 different institutions


    .


    The study included 88 patients with advanced NSCLC who received chemotherapy combined with immunotherapy in 6 different institutions


    The ORR of patients treated with docetaxel combined with ramucirumab was significantly better than that of patients with single-agent chemotherapy (55.


    Efficacy evaluation

    Efficacy evaluation

    The median PFS and OS of patients with advanced NSCLC who received second-line treatment were 5.


    0 months and 11.


    The median PFS and OS of patients with advanced NSCLC who received second-line treatment were 5.


    Prognostic analysis

    Prognostic analysis

    In the docetaxel + ramucirumab regimen group, patients with PFS ≥8.


    8 months of chemotherapy combined with immunotherapy (n = 8) had significantly longer PFS in second-line therapy than patients with PFS of chemotherapy combined with immunotherapy <8.


    In the docetaxel + ramucirumab regimen group, patients with PFS ≥8.


    Finally, the prognostic factors of second-line treatment after chemotherapy combined with immunotherapy in patients with advanced NSCLC were also studied


    PFS and OS factor analysis

     PFS and OS factor analysis

    In the docetaxel combined with ramucirumab group, the incidence of grade ≥3 neutropenia was 16.


    7%


    In the docetaxel combined with ramucirumab group, the incidence of grade ≥3 neutropenia was 16.
    7%
    .
    In the single-agent chemotherapy group, the incidence of grade 3 neutropenia was 33.
    3%
    .
    There was no significant difference in the incidence of grade ≥3 hematology (p = 0.
    13) and non-hematological toxicity (p = 0.
    58) between the docetaxel combined with ramucirumab and the single-agent chemotherapy group
    .
    There were no treatment-related deaths in either group
    .

    AEs

    AEsAEs

    In summary, this retrospective study shows that in the second-line treatment of advanced NSCLC patients, patients with longer progression-free survival who receive chemotherapy combined with immunotherapy are expected to benefit from docetaxel plus ramucirumab treatment
    .

    In summary, this retrospective study shows that in the second-line treatment of advanced NSCLC patients, patients with longer progression-free survival who receive chemotherapy combined with immunotherapy are expected to benefit from docetaxel plus ramucirumab treatment
    .
    This retrospective study showed that in the second-line treatment of advanced NSCLC patients, patients with longer progression-free survival who received chemotherapy combined with immunotherapy are expected to benefit from docetaxel plus ramucirumab treatment
    .
    This retrospective study showed that in the second-line treatment of advanced NSCLC patients, patients with longer progression-free survival who received chemotherapy combined with immunotherapy are expected to benefit from docetaxel plus ramucirumab treatment
    .

    Original source:

    Original source:

    Ishida M, Morimoto K, Yamada T, Shiotsu S, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Tokuda S, Takeda T, Takayama K.
    Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
    Thorac Cancer.
    2021 Nov 17.
    doi: 10.
    1111/1759-7714.
    14236.
    Epub ahead of print.
    PMID: 34791812.

    Ishida M, Morimoto K, Yamada T, Shiotsu S, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Tokuda S, Takeda T, Takayama K.
    Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
    Thorac Cancer.
    2021 Nov 17.
    doi: 10.
    1111/1759-7714.
    14236.
    Epub ahead of print.
    PMID: 34791812.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.